X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Blacksmith metalloenzyme platform, a focused library of metal-binding pharmacophores with proprietary computational modeling, approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzyme's active site.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Blacksmith Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 02, 2023
Details:
Under this agreement, Roche has an exclusive option to license one of Forge’s antibiotic programmes. Forge will retain control of the programme prior to Roche exercising its option.
Lead Product(s): Antibiotics
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $190.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
